What is Muna Therapeutics?
Muna Therapeutics operates at the intersection of advanced molecular biology and clinical neurology, dedicated to the discovery and development of novel therapies designed to arrest the progression of debilitating neurodegenerative diseases. The company's core focus encompasses Alzheimer’s, Frontotemporal Dementia, and Parkinson’s disease—conditions that profoundly impact cognitive function, motor skills, and personality. By leveraging a sophisticated scientific platform, Muna Therapeutics aims to translate complex biological insights into actionable treatments, addressing the underlying pathology of these disorders rather than merely managing symptoms. This approach positions the firm as a key player in the global effort to mitigate the socioeconomic and personal burdens associated with age-related neurological decline.
How much funding has Muna Therapeutics raised?
Muna Therapeutics has raised a total of $73M across 1 funding round:
Series A
$73M
Series A (2021): $73M with participation from DROIA Ventures, Novo Holdings, Sofinnova Partners, and LSP Dementia Fund
Key Investors in Muna Therapeutics
DROIA Ventures
A specialized venture capital firm focused on oncology and neurodegenerative disease investments, providing both financial backing and deep scientific expertise.
Novo Holdings
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation. The company was established in 1999 and is headquartered out of Hellerup, Denmark.
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
What's next for Muna Therapeutics?
With the recent infusion of capital, Muna Therapeutics is poised to transition from early-stage discovery into more robust clinical validation phases. The strategic roadmap likely involves expanding its proprietary drug candidate portfolio and strengthening its internal research infrastructure to expedite the path toward human clinical trials. As the company scales, the focus will remain on optimizing its therapeutic modalities to ensure high efficacy and safety profiles. Investors are closely monitoring the firm's ability to navigate the complex regulatory landscape of neuro-therapeutics, with the expectation that these resources will facilitate the necessary milestones to attract further institutional interest or potential pharmaceutical partnerships in the coming years.
See full Muna Therapeutics company page
